Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Bicocca Epidemiological Assessment of Cardiovascular Risk Factors

NCT07207603 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-06-17
Last updated
2025-10-06

Condition(s) studied

Cardiovascular Risk Factors (e.g., Hypertension)

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

The main objective of the study is to characterize the cardiovascular risk profile of the population in the Bicocca district through the evaluation of the exposome and the assessment of traditional and less studied cardiovascular risk factors for cardiovascular disease.

Eligibility

Sex
ALL
Min age
25 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals living in the area close to University Milano-Bicocca (postcode 20126) Exclusion Criteria: * Inability to sign the informed consent

Primary outcome measure(s)

  • Exposome — prior index date and at baseline visit
    to define the prevalence of the exposome associated with increased CV risk in an urban population. The exposome includes the following domains: 1. Internal: internal biological processes such as oxidative stress, inflammation, epigenetic changes, metabolism and the internal microbiome. 2. General external: social, economic factors, the urban environment and climate factors. 3. Specific external: an individual's immediate local environment, including exposure to chemicals, diet, physical activity, tobacco and infections.

Trial sites (1)

FacilityCityRegionStatus
University of Milan-Bicocca Milan Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07207603 on ClinicalTrials.gov ↗ ← All trials in Italy